secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001847903-23-000150
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa doses first subject in registrational PRESent-2 study for SerpinPC in hemophilia B
--------------------------------------------------------------------------------

- Dosed first patient in PRESent-2, a Phase 2b registrational study of SerpinPC for hemophilia B without inhibitors.
- Interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of the adaptive design.
- SerpinPC is a subcutaneously administered APC inhibitor; potential first-in-class therapy for hemophilia B.
- Company expects to start registrational PRESent-3 study for hemophilia B with inhibitors later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000150/0001847903-23-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000150/cnta-20230710.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer